AR095104A1 - Método para disminuir el dolor articular inducido por el ejercicio en mamíferos no artríticos - Google Patents

Método para disminuir el dolor articular inducido por el ejercicio en mamíferos no artríticos

Info

Publication number
AR095104A1
AR095104A1 ARP140100320A ARP140100320A AR095104A1 AR 095104 A1 AR095104 A1 AR 095104A1 AR P140100320 A ARP140100320 A AR P140100320A AR P140100320 A ARP140100320 A AR P140100320A AR 095104 A1 AR095104 A1 AR 095104A1
Authority
AR
Argentina
Prior art keywords
exercise
decreasing
collagen
pain induced
articular pain
Prior art date
Application number
ARP140100320A
Other languages
English (en)
Spanish (es)
Inventor
C Lau Francis
Lugo James
Dijkstra Paul
Original Assignee
Interhealth Nutraceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interhealth Nutraceuticals Inc filed Critical Interhealth Nutraceuticals Inc
Publication of AR095104A1 publication Critical patent/AR095104A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP140100320A 2013-10-24 2014-01-30 Método para disminuir el dolor articular inducido por el ejercicio en mamíferos no artríticos AR095104A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361895332P 2013-10-24 2013-10-24

Publications (1)

Publication Number Publication Date
AR095104A1 true AR095104A1 (es) 2015-09-30

Family

ID=51610711

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100320A AR095104A1 (es) 2013-10-24 2014-01-30 Método para disminuir el dolor articular inducido por el ejercicio en mamíferos no artríticos

Country Status (14)

Country Link
US (1) US9066926B2 (enExample)
KR (1) KR101664290B1 (enExample)
AR (1) AR095104A1 (enExample)
AU (1) AU2014202041B8 (enExample)
BR (1) BR112014011741A2 (enExample)
CA (1) CA2846644C (enExample)
CL (1) CL2014001281A1 (enExample)
CO (1) CO7020846A2 (enExample)
IN (1) IN2014DE00193A (enExample)
MX (1) MX347669B (enExample)
MY (1) MY180106A (enExample)
PH (1) PH12014501453A1 (enExample)
SG (1) SG11201403524RA (enExample)
WO (1) WO2015060888A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10226513B2 (en) 2015-01-09 2019-03-12 Mark Terrell Smith Method and composition to prevent or improve symptoms of musculoskeletal distress degeneration
US20180078768A1 (en) * 2016-09-16 2018-03-22 Boston Scientific Neuromodulation Corporation Method and apparatus for pain management using heart sounds
US10610688B2 (en) 2016-09-27 2020-04-07 Boston Scientific Neuromodulation Corporation Systems and methods for closed-loop pain management
AU2017335497B2 (en) 2016-09-27 2020-01-16 Boston Scientific Neuromodulation Corporation System for pain management using objective pain measure
US11793217B1 (en) 2016-10-04 2023-10-24 Lonza Greenwood Llc Method of manufacture and pasteurization of products containing undenatured collagen
EP3526007A4 (en) 2016-10-12 2020-05-27 Advanced Biomatrix, Inc. THREE-DIMENSIONAL (3-D) PRINTING INKS MANUFACTURED FROM NATURAL EXTRACELLULAR MATRIX MOLECULES
EP3532155B1 (en) 2016-10-25 2025-08-27 Boston Scientific Neuromodulation Corporation System for pain management using baroreflex sensitivity
WO2018132529A1 (en) 2017-01-11 2018-07-19 Boston Scientific Neuromodulation Corporation Pain management based on brain activity monitoring
US11089997B2 (en) 2017-01-11 2021-08-17 Boston Scientific Neuromodulation Corporation Patient-specific calibration of pain quantification
US10631776B2 (en) 2017-01-11 2020-04-28 Boston Scientific Neuromodulation Corporation Pain management based on respiration-mediated heart rates
US10631777B2 (en) 2017-01-11 2020-04-28 Boston Scientific Neuromodulation Corporation Pain management based on functional measurements
US10729905B2 (en) 2017-01-11 2020-08-04 Boston Scientific Neuromodulation Corporation Pain management based on muscle tension measurements
WO2018132535A1 (en) 2017-01-11 2018-07-19 Boston Scientific Neuromodulation Corporation Pain management based on emotional expression measurements
US10960210B2 (en) 2017-02-10 2021-03-30 Boston Scientific Neuromodulation Corporation Method and apparatus for pain management with sleep detection
CN106713191B (zh) * 2017-02-28 2020-09-08 西安电子科技大学 一种多级搜索sage方法
CN107048412A (zh) * 2017-04-26 2017-08-18 北京盛美诺生物技术有限公司 一种含有ⅱ型胶原蛋白的咀嚼型产品
AU2018304079B2 (en) 2017-07-18 2020-12-03 Boston Scientific Neuromodulation Corporation Sensor-based pain management systems and methods
CN111163797A (zh) * 2017-08-21 2020-05-15 伦萨有限责任公司 组合物和由其制备的营养补剂
CN111093770A (zh) * 2017-08-31 2020-05-01 伦萨有限责任公司 健康促进组合物和使用补剂方法的相关应用
IT201700111939A1 (it) * 2017-10-05 2019-04-05 Jointherapeutics S R L Composizione farmaceutica per l’uso nel trattamento di stati infiammatori
WO2020018504A1 (en) * 2018-07-16 2020-01-23 Lonza Inc. Collagen and cell matter supplement and method for administering same
WO2021016665A1 (en) * 2019-07-30 2021-02-04 Atp Institute Pty Ltd A gummy composition
US20220331406A1 (en) * 2019-09-30 2022-10-20 Lonza Consumer Health Inc. Cannabinoid Product for Improving Musculoskeletal Health
US20230248808A1 (en) * 2020-01-29 2023-08-10 Lonza Greenwood Llc Joint Health Composition and Use Thereof in Healthy Mammals
WO2021178291A1 (en) 2020-03-03 2021-09-10 Lonza Consumer Health Inc. Undenatured type ii collagen in food and beverage applications and uses thereof
JP2023518688A (ja) 2020-03-24 2023-05-08 ロンザ・グリーンウッド・エルエルシー 動物用食品およびおやつにおける非変性ｉｉ型コラーゲン
WO2021252612A1 (en) * 2020-06-12 2021-12-16 Lonza Consumer Health Inc. Undenatured type ii collagen as a supplement for improved endurance, lipid metabolism, and oxidative stress
WO2022040026A1 (en) * 2020-08-19 2022-02-24 Lonza Consumer Health Inc. Method for improving inflammation, joint health, joint mobility, and joint comfort in healthy mammals
CN115120618B (zh) * 2021-03-23 2024-01-26 安徽盛美诺生物技术有限公司 具有改善免疫应答作用的软骨提取物、其制备方法及其用途
CN118215494A (zh) * 2021-11-12 2024-06-18 龙沙格林伍德有限公司 用于治疗骨骼关节的方法以及其组合物和用途
KR102771944B1 (ko) * 2023-09-25 2025-02-26 (주)온오퍼 고함량 액티브 성분을 갖는 반려동물용 츄 형태 영양제

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399347A (en) 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
EP0565678A1 (en) 1991-11-08 1993-10-20 LOFGREN NISSER, Gunilla Partially occluded contact lens for treating visual and/or brain disorder
US5529786A (en) 1994-02-28 1996-06-25 Moore; Eugene R. Process and product for treatment of rheumatoid arthritis
US5637321A (en) 1994-02-28 1997-06-10 Moore; Eugene R. Method for preparing animal tissue for use in alleviating the symptoms of arthritis in mammals
US5645851A (en) 1994-02-28 1997-07-08 Moore; Eugene R. Product for alleviating the symptons of arthritis in mammals
US6162787A (en) * 1999-04-02 2000-12-19 Immudyne, Inc. Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions
US6372794B1 (en) * 1999-08-26 2002-04-16 Marcel E. Nimni Method for alleviating arthritis in mammals
US20020086070A1 (en) 2000-03-11 2002-07-04 Kuhrts Eric Hauser Anti-inflammatory and connective tissue repair formulations
US7083820B2 (en) 2000-09-29 2006-08-01 Schilling Marvin L Method for producing biologically active products
JP2003048850A (ja) 2001-06-01 2003-02-21 Nippon Meat Packers Inc 関節傷害治療剤及び機能性食品
US20060062859A1 (en) * 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes
FR2900155B1 (fr) * 2006-04-21 2008-06-27 Diana Naturals Sa Hydrolisat de cartilage aviaire, procede d'obtention et utilisations
US20100215731A1 (en) 2009-02-20 2010-08-26 Maastricht University Method for improving cartilage repair and/or preventing cartilage degeneration in a joint
US20110218151A1 (en) * 2010-03-04 2011-09-08 Joar Opheim Substances for promoting healthy joint function comprising omega-3 polyunsaturated fatty acids or drivatives thereof, undenatured type ii collagen and, optionally, glucosamine sulfate
CN101822684B (zh) 2010-05-27 2012-08-15 江苏江山制药有限公司 用于防治骨关节痛的复方组合制剂及其制备方法
US20120294898A1 (en) 2011-05-19 2012-11-22 Warsaw Orthopedic, Inc. Injectable dbm for soft tissue repair
CN102423487B (zh) 2011-12-23 2014-04-16 内蒙古伊利实业集团股份有限公司 一种骨关节保健组合物及其应用
CN103203012A (zh) 2012-01-12 2013-07-17 深圳市麦金利实业有限公司 关节保健品

Also Published As

Publication number Publication date
AU2014202041B8 (en) 2020-04-02
US9066926B2 (en) 2015-06-30
KR101664290B1 (ko) 2016-10-11
WO2015060888A1 (en) 2015-04-30
MY180106A (en) 2020-11-23
CL2014001281A1 (es) 2015-10-30
US20150119335A1 (en) 2015-04-30
CA2846644A1 (en) 2015-07-13
AU2014202041B2 (en) 2019-11-28
MX2014002934A (es) 2015-09-21
CA2846644C (en) 2018-05-01
CO7020846A2 (es) 2014-08-11
BR112014011741A2 (pt) 2017-05-30
PH12014501453B1 (en) 2015-01-21
PH12014501453A1 (en) 2015-01-21
SG11201403524RA (en) 2015-05-28
MX347669B (es) 2017-05-08
AU2014202041A1 (en) 2015-05-14
KR20150059132A (ko) 2015-05-29
IN2014DE00193A (enExample) 2015-05-01

Similar Documents

Publication Publication Date Title
AR095104A1 (es) Método para disminuir el dolor articular inducido por el ejercicio en mamíferos no artríticos
BR112015014420A2 (pt) oligossacarídeos do leite humano para melhorar sintomas de estresse
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
UA122342C2 (uk) Спосіб інгібування всмоктування та/або прискорення виведення ліпідів за допомогою d-псикози
MX373270B (es) Composiciones y metodos para mejorar el rendimiento del ejercicio.
CO2017007874A2 (es) Composiciones y métodos para metabolismo muscular mejorado
ECSP13012798A (es) Método para inhibir patógenos usando una composición nutricional
EA201992382A2 (ru) Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения
BR112016017765A8 (pt) composição compreendendo cinamaldeído e zinco, seu uso, e método para produzir um produto alimentício para perda de peso
EA201270573A1 (ru) Гранулированный в расплаве цинакальцет
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
UA108200C2 (uk) Лікарські форми та способи застосування ектопаразитоцидів
AR100028A1 (es) Composiciones nutricionales que contienen ácido estearidónico
AR088752A1 (es) Composiciones y metodos para proporcionar una dieta adecuada para animales segun la etapa de la vida
UY32507A (es) Una dosis de ave5026 para el tratamiento de trombormbolismo venoso en pacientes con deterioro renal severo
CL2015001104A1 (es) Composición de la alimentación para peces
CL2017002931A1 (es) Método para incrementar la utilización de proteína de soja por peces salmónidos.
CR20160021A (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
ES2544780T3 (es) Metadoxina para su uso como inhibidor de fibrosis hepática
CL2008002828A1 (es) Tableta oral que comprende una cantidad mayor de 38% de alisquireno o una de sus sales y fosfato acido de calcio como relleno.
BR112016012233A8 (pt) composições compreendendo cinamaldeído, e seus usos
MX2017007856A (es) Composicion para el cuidado bucal.
AR095082A1 (es) Solución electrolítica oral que contiene lactoferrina y método asociado a la reducción de la duración de la diarrea
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
MX2018005881A (es) Suplemento dietético que comprende beta-glucano e hidrolizado de caseína para mejorar la salud y el desempeño del crecimiento de un mamifero.

Legal Events

Date Code Title Description
FB Suspension of granting procedure